Since the overwhelming majority of post-ACS patients in ODYSSEY Outcomes had PCI as part of their ACS management, what have we learned about the safety and efficacy of alirocumab in this stent-rich population of high-risk patients?

Since the overwhelming majority of post-ACS patients in ODYSSEY Outcomes had PCI as part of their ACS management, what have we learned about the safety and efficacy of alirocumab in this stent-rich population of high-risk patients?

Since the overwhelming majority of post-ACS patients in ODYSSEY Outcomes had PCI as part of their ACS management, what have we learned about the safety and efficacy of alirocumab in this stent-rich population of high-risk patients?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Andreas Zeiher, MD

Andreas Zeiher, MD

Chairman of Medicine Department of Cardiology, Angiology, and Nephrology J. W. Goethe University Frankfurt, Germany